Ultragenyx reported failure in two phase‑3 trials for brittle bone disease and announced plans for major cost reductions. The late‑stage setbacks forced management to reassess R&D priorities and prepare significant spending cuts to preserve runway. The trial failures remove near‑term prospects for the company’s brittle bone program and will ripple through investor expectations and partner negotiations. Pipeline teams and investors should expect accelerated prioritization of core assets and potential restructuring of development timelines.